Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
269 participants
OBSERVATIONAL
2022-05-01
2023-12-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ICU Venous Thromboembolism Incidence Study in a Chinese Population
NCT01504087
Thromboembolic Complications in COVID-19 Patients in Intensive Care Unit
NCT06037707
Diagnostic Value of sTREM-1 and PCT Level as Well as CPIS Score for Ventilator-Associated Pneumonia Among ICU Sepsis Patients
NCT01406951
Pronostic Value of Fluid Responsiveness Evaluated by Inferior Vena Cava Collapsibility Index in Patients Admitted in ICU With Acute Respiratory Failure
NCT06286306
Frequency, Predictors and Outcome of Sepsis Induced Coagulopathy in Critical Care Unit
NCT06586346
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study was designed according to a prospective study method. Data and information were collected from the time the patients were admitted to the ICU to the time the patients were discharged from the ICU.There are three purposes for this study. First, to observe the predictive effect and evaluate the value of the ICU-VTE scoring scale in comprehensive ICU patients; Second, to compare the advantages and disadvantages of the ICU-VTE scoring tool with the Padua score (internal medicine) and Caprini score tool (surgery); To analyze the risk factors for VTE in comprehensive ICU patients and to optimize the VTE risk prediction model; Third, to look into the prevention and treatment of VTE in critically ill ICU patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients or their family members agreed to the study and signed informed consent.
Exclusion Criteria
* Use the therapeutic dose of anticoagulation before admission to ICU or within 24 hours in ICU;
* Expected ICU stay of less than 48 hours;
* Patients cannot obtain imaging data to confirm the presence of VTE during ICU admission
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lijuan Zhang
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lijuan Zhang
physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Juan Li Zhang, Master
Role: PRINCIPAL_INVESTIGATOR
Intensive Care Unit, the Central Hospital of Wuhan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Central Hospital of Wuhan
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WHZXKYL2022-117
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.